Results 331 to 340 of about 775,670 (354)

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Nature Reviews Clinical Oncology, 2009
Helena Linardou, Samuel Murray
exaly  

Targeting the human EGFR family in esophagogastric cancer

Nature Reviews Clinical Oncology, 2011
Alicia F C Okines, David Cunningham, Ian Chau   +2 more
exaly  

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

The Lancet Oncology, 2014
Yi-long Wu, Caicun Zhou, Cheng-ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, M. Hou, Jianhua Shi, K. Lee, Chongrui Xu, D. Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater   +14 more
semanticscholar   +1 more source

Integration of EGFR inhibitors with radiochemotherapy

Nature Reviews Cancer, 2006
Mukesh K Nyati, Theodore S Lawrence
exaly  

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Nature Reviews Cancer, 2010
William Pao
exaly  

Feedback regulation of EGFR signalling: decision making by early and delayed loops

Nature Reviews Molecular Cell Biology, 2011
Roi Avraham, Yosef yarden
exaly  

EGFR Mutations

2019
Anna Manzo, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Giuliano Palumbo, Clorinda Schettino, Gennaro Daniele, Alessandro Morabito, Francesco Perrone, Maria Carmela Piccirillo   +9 more
openaire   +1 more source

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Maxime Borgeaud, Jair Bar, Stephanie Saw
exaly  

Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer

Cancer Cell, 2018
Pei-chih Lee, Yueh-Fu Fang, Hirohito Yamaguchi   +2 more
exaly  

EGFR

2008
openaire   +1 more source